利拉鲁肽治疗2型糖尿病的临床研究进展  

Clinical Research Progress of Liraglutide in the Treatment of Type 2 Diabetes

作　　者：许美玲[1] 仇雨轩 于俊杰[1] 李琳娜[1] 杨傅铭 张艾[1] 詹晓蓉[1] 

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2015年第3期598-600,共3页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅基金项目(12511233)

摘　　要：利拉鲁肽是一种新型胰高糖素样肽-1 GLP-1类似物,能迅速、高效、持久地降低血糖及糖化血红蛋白,具有改善胰岛β细胞功能、调节收缩压、保护心血管、降低血脂、减轻体重、延迟胃排空、增加饱腹感等作用。此外,利拉鲁肽具有葡萄糖依赖的促胰岛素分泌作用,仅在机体血糖水平高时刺激胰岛素的释放,但当患者体内血糖浓度恢复至正常时,GLP-1分泌促胰岛素的作用便消退,因而发生低血糖事件的几率较低,能有效地改善糖尿病患者的病情,已成为目前2型糖尿病治疗领域的研究热点。本文主要就利拉鲁肽治疗2型糖尿病的临床研究进展进行综述。Liraglutide was a new kind of glicagon like pepfide-1 （GLP-1）, which could decrease the blood glucose and glycated hemoglobin levels rapidly, efficiently and lastingly, and had some effects on improving the islet cell function, regulating systolic pressure, protecting cardiovascular, lowing blood lipids, decreasing body weight, delaying gastric emptying, increasing satiety and so on. In addition, liraglutide could promote the secretion of insulin on a glucose-dependent manner, and it could stimulate the release of insulin only in high blood glucose levels, but when patients＇ blood glucose returned to normal, the effect of GLP-1 would disappeare, thus the incidence of hypoglycemia was lowered, and the state of diabetes was improved, which had become the hot spot of the field of treatment of type 2 diabetes. This article mainly reviewed the clinical research progress of liraglutide in the treatment of type 2 diabetes.

关 键 词：利拉鲁肽 胰高糖素样肽-1 2型糖尿病 临床研究 

分 类 号：R587.1[医药卫生—内分泌]